⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16283404 | 0.80 | NPSR1 (0.32) | — | |
| SCHEMBL19226758 | 0.78 | TSHR (0.46) | — | |
| SCHEMBL15224399 | 0.78 | SMN1; SMN2 (0.41) | — | |
| SCHEMBL17284646 | 0.75 | POLB (0.45) | — | |
| SCHEMBL23007791 | 0.75 | — | — | |
| SCHEMBL1382164 | 0.75 | — | — | |
| SCHEMBL20980235 | 0.74 | — | — | |
| SCHEMBL25668133 | 0.74 | — | — | |
| SCHEMBL23892730 | 0.73 | SMN1; SMN2 (0.59) | — | |
| SCHEMBL24532104 | 0.73 | SIGMAR1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725010-B2 | Polyheterocyclic compounds as METTL3 inhibitors | STORM THERAPEUTICS LIMITED (GB) | 2023-08-15 | — | — | US | disclosed |
| WO-2023107714-A2 | METHODS FOR TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2023-06-15 | — | — | WO | disclosed |
| US-20230002378-A1 | POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS | STORM THERAPEUTICS LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20200369676-A1 | HETEROCYCLIC COMPOUND, APPLICATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-26 | — | — | US | disclosed |
| US-10829490-B2 | Substituted dihydropyrazino[1 ′,2′:1,5]pyrrolo[2,3-d]pyrimidine-based antiproliferative agents | GI Therapeutics, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| US-20190135811-A1 | PYRIMIDINE-BASED ANTIPROLIFERATIVE AGENTS | G1 THERAPEUTICS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| EP-2583098-B1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORP (US) | 2018-08-08 | — | — | EP | disclosed |